Latest Cancer TreatmentsDr. Mohammadreza Dabiri
Dr. Mohammadreza Dabiriفارسی
Physician lesson

Malignant pleural effusion: drainage, pleurodesis or an indwelling catheter

Based on the ERS/EACTS statement

Updated: 28 October 20261 min read1 reference

Key points

  • An asymptomatic malignant effusion needs no interventional treatment [1].
  • Drain symptomatic effusions under ultrasound guidance [1].
  • Recurrent effusion with an expandable lung: talc pleurodesis or an indwelling catheter according to the patient's preference [1].
  • Non-expandable lung: an indwelling catheter [1].

Approach

  1. 1

    Diagnosis

    Fluid cytology (limited sensitivity; if negative with high suspicion, pleural biopsy or thoracoscopy) [1].

  2. 2

    First drainage

    Therapeutic drainage to relieve symptoms and to see whether breathlessness improves and the lung re-expands [1].

  3. 3

    Definitive treatment

    If the fluid returns: talc (by thoracoscopy or chest drain) or a tunnelled indwelling catheter; both improve breathlessness, and the catheter means a shorter hospital stay [1].

  4. 4

    Non-expandable lung

    Pleurodesis usually fails; an indwelling catheter is the choice [1].

In practice

In lymphoma, breast cancer, small cell lung cancer and treatment-sensitive tumours, effective systemic treatment may control the fluid.

Related cancer types

Breast cancerLung cancer

Treatment regimens (physicians)

AC followed by paclitaxel (dose-dense and weekly)TC regimen (docetaxel and cyclophosphamide): dose and scheduleTCHP regimen: dose and schedule in HER2-positive breast cancerWeekly paclitaxel with trastuzumab (APT regimen)KEYNOTE-522 regimen: pembrolizumab and chemotherapy in triple-negative breast cancerTrastuzumab emtansine (T-DM1, Kadcyla): dose and scheduleTrastuzumab deruxtecan (T-DXd, Enhertu): dose and monitoringAdjuvant capecitabine after neoadjuvant treatment (CREATE-X)Sacituzumab govitecan (Trodelvy)Pembrolizumab with chemotherapy in metastatic triple-negative breast cancer (KEYNOTE-355)Carboplatin, pemetrexed and pembrolizumab (KEYNOTE-189)Carboplatin, paclitaxel and pembrolizumab (KEYNOTE-407)

Physician tools and lessons

Cumulative Anthracycline Dose and Doxorubicin EquivalentsKhorana Score (Cancer-Associated Thrombosis Risk)Should I Be Screened for Lung Cancer? (Pack-Year Calculator)10 cheap steps that save patients' livesBone-modifying agents in cancer: bone metastases, adjuvant use and osteonecrosis of the jawGermline genetic testing in cancer: who, and which genes?Management of brain metastasesFertility preservation before cancer treatmentCancer during pregnancy: chemotherapy and decisions

References

1 reference
Show all referencesClose the reference list

Numbers in the text, such as [1], refer to these sources. Sources with a “Study card” button are summarised in the site’s evidence library.

  1. 1
    ERS/EACTS statement on the management of malignant pleural effusionsBibby AC, Dorn P, Psallidas I, et al · Eur Respir J · 2018;52
    DOIPubMed Back to text: 1 2 3 4 5 6 7 8

This page is based on reputable scientific sources and was last updated on 28 October 2026. The content of this website is for educational and informational purposes only and does not replace consultation, diagnosis or treatment by a specialist physician. Consult your treating physician about any treatment decision.

Printed from the website; the full and up-to-date version: https://drdabiri.com/en/learn/malignant-pleural-effusion/

Related pages

26 October 2026 10 cheap steps that save patients' lives Ten cheap, accessible actions with strong evidence for emergency, oncology, surgical and primary care doctors: from immediate tretinoin in APL and antibiotics within 1 hour to zoledronic acid, BRCA, EGFR and MMR testing, morphine and short-course radiotherapy. 27 October 2026 Management of brain metastases Guideline-based management of brain metastases: radiosurgery for 1 to 4 lesions, hippocampal-avoidance whole-brain radiotherapy with memantine, and systemic treatment in EGFR/ALK lung cancer and BRAF melanoma. 27 October 2026 Cancer of unknown primary (CUP) A guide to assessing and treating cancer of unknown primary: an immunohistochemistry panel, imaging, favourable subsets with specific treatment, and the place of molecular profiling.